Provided by Tiger Fintech (Singapore) Pte. Ltd.

Biohaven Pharmaceutical Holding Co Ltd.

21.98
-0.6400-2.83%
Volume:112.95K
Turnover:2.48M
Market Cap:2.24B
PE:-2.37
High:22.22
Open:22.00
Low:21.74
Close:22.62
Loading ...

Merus, Biohaven Partner to Develop Bispecific Therapies for Cancers

MT Newswires Live
·
13 Jan

BRIEF-Merus And Biohaven Announce Collaboration To Co-Develop Three Novel Bispecific ADC Programs

Reuters
·
13 Jan

Biohaven - Agreement Includes Two Merus Bispecific Programs Generated Using Biclonics Platform

THOMSON REUTERS
·
13 Jan

Biohaven Ltd - Co Is Responsible for Preclinical ADC Generation of Three Merus Bispecific Antibodies Under Mutually Agreed Research Plans

THOMSON REUTERS
·
13 Jan

Biohaven Ltd - Merus Will Receive an Upfront Payment and License Fee at ADC Candidate Nomination of First Program

THOMSON REUTERS
·
13 Jan

Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs

GlobeNewswire
·
13 Jan

Insider Buying: Biohaven Independent Director Bought US$1.0m Of Shares

Simply Wall St.
·
03 Jan

Company News for Jan 2, 2025

Zacks
·
02 Jan

Biohaven rises 6.1%

TIPRANKS
·
31 Dec 2024

Biohaven Advances in Immunotherapy: Significant IgG Reduction Achieved with BHV-1300, Gains Analyst Approval

Benzinga
·
18 Dec 2024

Biohaven Price Target Maintained With a $59.00/Share by HC Wainwright & Co.

Dow Jones
·
17 Dec 2024

Is Biohaven Ltd. (BHVN) the Best Weight Loss Stock to Buy Now According to Hedge Funds?

Insider Monkey
·
17 Dec 2024

Bernstein Reaffirms Their Buy Rating on Biohaven Ltd. (BHVN)

TIPRANKS
·
17 Dec 2024

BRIEF-Biohaven Reports Phase 1 Degrader Data; Announces NDA Submission For Troriluzole In SCA

Reuters
·
16 Dec 2024

BUZZ-Biohaven rises on positive early-stage antibody drug trial results

Reuters
·
16 Dec 2024

Biohaven Says BHV-1300 Achieves 'Deep Lowering' of Targeted IgG During Early-Stage Trial

MT Newswires Live
·
16 Dec 2024

Biohaven reports clinical, regulatory milestones across MoDE platform

TIPRANKS
·
16 Dec 2024

Biohaven Ltd - Bhv-1300 Safe and Well Tolerated in Phase 1

THOMSON REUTERS
·
16 Dec 2024

Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted Igg Reductions in the Lowest Subcutaneous Dose Tested; Announces Nda Submission for Troriluzole in SCA and Provides Other Key Program Updates

THOMSON REUTERS
·
16 Dec 2024

Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program Updates

PR Newswire
·
16 Dec 2024